表紙:ワクチン受託製造市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
市場調査レポート
商品コード
1037209

ワクチン受託製造市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)

Vaccine Contract Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 142 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
ワクチン受託製造市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
出版日: 2021年11月10日
発行: IMARC Services Private Limited
ページ情報: 英文 142 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のワクチン受託製造の市場規模は、2015年~2020年にかけて力強い成長を示しました。同市場は今後、2021年~2026年の間に約9%のCAGRで拡大すると予測されています。

ワクチン接種は、人や動物の健康増進に極めて重要な役割を果たします。また抗生物質の必要性を減らし、病気を予防します。ワクチン接種に対する認識が高まり、重篤な病気や感染症から身を守ることができるなど、多くの利点があることから、予防接種プログラムの需要が高まっています。さらに、多くの国でコロナウイルス感染症(COVID-19)の症例が憂慮すべきほど増加していることから、ワクチン開発会社はCMOとアウトソーシング契約を結ぶようになっています。これにより、市場の成長が期待されています。

当レポートでは、世界のワクチン受託製造市場について調査し、市場の概要とともに、ワクチンタイプ別、ワークフロー別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のクチン受託製造市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場の内訳、ワクチンタイプ別

  • 弱毒化ワクチン
  • 不活化ワクチン
  • サブユニットワクチン
  • トキソイドワクチン
  • DNAワクチン

第7章 市場の内訳、ワークフロー別

  • 下流
    • キーセグメント
  • 上流
    • キーセグメント

第8章 市場の内訳、用途別

  • ヒト用
  • 動物用

第9章 市場の内訳、地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場の内訳

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited(Charles River Laboratories International Inc.)
    • Cytovance Biologics Inc.(Hepalink USA Inc.)
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
目次
Product Code: SR1020G230_Report

The global vaccine contract manufacturing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, workflow and application.

Breakup by Vaccine Type:

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Breakup by Workflow:

  • Downstream
  • Fill and Finish Operations
  • Analytical and QC studies
  • Packaging
  • Upstream
  • Mammalian Expression Systems
  • Bacterial Expression Systems
  • Yeast Expression Systems
  • Baculovirus/Insect Expression Systems
  • Others

Breakup by Application:

  • Human Use
  • Veterinary

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report:

  • How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the workflow?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global vaccine contract manufacturing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials